| BACKGROUND
Mechanistic target of rapamycin (mTOR), a serine/threonine proteinkinase,regulatesavarietyofcellularfunctions, includingsurvivalandcellproliferationaswellasinnateandadaptativeimmune response [1] (s1).Interferingwithotherproteins,itformstwocomplexes: mTOR signalling complex (mTORC) 1, responsible for the increaseincellgrowthandproliferation,andmTORC2,involvedin theregulationofcellpolarityandphosphorylationofcytoskeleton actin fibres. [1] These complexes recognize many upstream signals anddownstreameffectors.Oneofthemainupstreammodulatorsof mTORC1istumornecrosisfactor(TNF)-α. [1, 2] Inparticular,TNF-α suppresses tuberous sclerosis (TSC) 1 resulting in mTORC1 activation. [3] When active, mTORC1 phosphorylates and activates its downstreameffectorribosomalproteinS6kinase1(S6K1)involved incellproliferation.
[1] SomeinflammatoryskindiseasesarecharacterizedbyelevatedlevelsofmTOR, [4] [5] [6] andtherearefewreports indicating an increase of mTOR and S6K1 in psoriasis too. [4, 7] Up tonow,thelinkbetweenmTORC1andTNF-α in psoriasis has not beenyetelucidatedeventhoughitiswellknownthatTNF-α is an upstream signal of mTORC1 and also one of main protagonists of the disease.
| QUESTION ADDRESSED
TheaimofthisstudywastoassesstheinvolvementofmTORC1sig-nallingaswellastoshedalightonthepossiblerelationshipbetween mTORC1andTNF-α in psoriasis.
| EXPERIMENTAL DESIGN
The study population comprised 28 patients with psoriasis and 10 healthycontrols.Of28patients,fiveunderwentanti-TNF-α therapy with previous data [4, 7] thatactivationofmTORsignallingmightbe involved in psoriasis pathogenesis and confirm its increasing relevanceinskininflammatoryprocess. [8] Furthermore,nodifferences Abbreviations:HS,healthyskin;LS,lesionalskin;mTORC,mTORsignallingcomplex;mTOR,mechanistictargetofrapamycin;NLS,non-lesionalskin;P-S6K1,phospho-S6-ribosomalprotein;
RT-PCR,real-timepolymerasechainreaction;S6K1,ribosomalproteinS6kinase1;TNF-α,tumornecrosisfactor-alpha;TSC,tuberoussclerosis.
We reported that all cytokines were downregulated, except for IL-1Ra and IL-36β. Taken together, these data suggest that the blockage of TNF-α improved psoriatic inflammatory milieu plus a morespecificdownregulationofmTORC1thantraditionalsystemic treatments.
| CONCLUSIONS
In our study, mTOR was significantly increased in NLS as well as LS of psoriatic subjects, both at gene and protein level, indicating thatitisinvolvedinpsoriasispathogenesis.Ourresultsareinline withpreviousstudies,whichfoundelevatedmTORlevelsinpsoriaticLSandsuggestapossibleroleofmTORpathwayinregulating keratinocytesimmuneresponseandcytokineproductioninpsoriasis. [2] WefoundthatS6K1and,inparticular,itsactivatedformPS6K1wereslightlypresentinhealthyskinbutstronglyatpsoriatic plaquelevelinaccordancewithBurgeretal., [7] suggestingthespe- and insulin resistance [9] (s7-S9). In this study, we showed, for the first time, that P-S6K1 was completely abolished after 12weeks of etanercept therapy, whereas it was still expressed after systemicretinoidtreatment,indicatingastrongeractionofanti-TNF-α agentonmTORC1.PreviousevidenceshowedthatsilencingmTOR leads to the inhibition of TNF-α-induced P-S6K1 (s10). Our data reinforced the hypothesis that TNF-α exerts its effects acting on mTORC1complex.
Inconclusion,mTORC1pathwayismodulatedbyanti-TNF-α treatment,highlightingapossiblenewmechanismbywhichTNF-α inhibitionimprovespsoriasis.
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